Know Cancer

forgot password

Phase II Randomized Open Label Study of Neo-Adjuvant Degarelix vs. LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy

Phase 2
18 Years
75 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Phase II Randomized Open Label Study of Neo-Adjuvant Degarelix vs. LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy

Inclusion Criteria:

- Men >18 and =< 75 years of age

- Willing and able to provide informed consent, either alone or with the aid of a

- Histologically confirmed prostate cancer as determined by transrectal ultrasound
(TRUS) guided prostate biopsy performed within 6 months of study enrolment

- Gleason Score < 7or prostate cancer that is clinical stage T2 disease.

- Candidates for open radical prostatectomy considered surgically resectable by
urologic evaluation

- Normal organ and marrow function as defined by the following criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

Exclusion Criteria:

- Previous or current use of hormonal management of prostate cancer (surgical
castration or other hormonal manipulation, including GnRH receptor agonists, GnRH
receptor antagonists, anti-androgens, estrogens, megestrol acetate, and ketoconazole)

- Planned Robotic or Laparoscopic radical prostatectomy

- History of receiving radiation to the pelvic area.

- Previously received therapy with 5-alpha reductase inhibitors finasteride and/or
dutasteride within 12 weeks and 25 weeks, respectively, prior to baseline

- History of bilateral orchiectomy, adrenalectomy, or hypophysectomy.

- History of severe untreated asthma, anaphylactic reactions, or severe urticaria
and/or angioedema.

- Known hypersensitivity towards any component of the investigational medicinal product
or Casodex (bicalutamide) or their excipients.

- Marked baseline prolongation of QT/QTcF interval (e.g. repeated demonstration of a
QTcF interval >450 ms).

- History of risk factors for Torsade de Pointes ventricular arrhythmias (e.g. heart
failure, hypokalemia, or family history of Long QT Syndrome).

- Previous history or presence of another malignancy, other than prostate cancer or
treated squamous / basal cell carcinoma of the skin, within the last five years.

- Clinically significant laboratory abnormalities (e.g. severe renal or hepatic
impairment) which in the judgment of the Investigator would affect the patient's
health or the outcome of the trial.

- Clinically significant disorder (other than prostate cancer) including, but not
limited to, renal, haematological, gastrointestinal, endocrine, cardiac,
neurological, or psychiatric disease, and alcohol or drug abuse or any other
condition, which may affect the patient's health or the outcome of the trial as
judged by the Investigator.

- Use of natural medicines, such as saw palmetto and St. John's Wort, thought to have
endocrine effects on prostate cancer

- Mental incapacity or language barrier precluding adequate understanding or co

- Use of an investigational drug within the last 28 days preceding the Screening Visit
or longer if considered to possibly influence the outcome of the current trial.

- Previously participated in any degarelix trial.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Intratumoral androgen levels

Outcome Time Frame:

Week 12

Safety Issue:



Canada: Health Canada

Study ID:




Start Date:

August 2012

Completion Date:

December 2014

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms